<DOC>
	<DOCNO>NCT01541956</DOCNO>
	<brief_summary>This open-labeled , randomize , multicenter , prospective , parallel group , interventional study demonstrate effectiveness 24 week treatment Vildagliptin 50mg bid add metformin 500 mg bid compare metformin 1000 mg bid Chinese patient type 2 diabetes inadequately control sub maximal dosage metformin monotherapy .</brief_summary>
	<brief_title>Efficacy VIldagliptin aS Add-on Therapy Metformin Compared Metformin Up-TitratION Chinese Patients With Type 2 Diabetes . ( VISION )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Chinese T2D patient inadequate control ( 6.5 % &lt; HbA1C ≤9 % ) metformin ( ≥750mg/d ≤1000mg/d , ≥12 week ) , Type 1 diabetes secondary diabetes Acute metabolic diabetic complication within past 3 month . Acute infection may influence glucose level . Evidence significant chronic diabetic complication , Clinically significant renal impairment hepatic impairment patient , include history cirrhosis chronic hepatitis , FPG &gt; 270 mg/dl ( 15 mmol/l ) Any follow disease within past 6 month : myocardial infarction ( MI ) ; coronary artery bypass surgery percutaneous coronary intervention ; unstable angina stroke ; Congestive heart failure ( CHF ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>type 2 diabetes ;</keyword>
	<keyword>vildagliptin ;</keyword>
	<keyword>metformin ;</keyword>
</DOC>